Adaptive Biotechnologies ADPT AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's AFS securities?
- Adaptive Biotechnologies (ADPT) reported AFS securities of $18.89M in Q1 2026.
- How has Adaptive Biotechnologies's AFS securities changed year-over-year?
- Adaptive Biotechnologies's AFS securities decreased by 52.0% year-over-year, from $39.36M to $18.89M.
- What is the long-term trend for Adaptive Biotechnologies's AFS securities?
- Over 3 years (2020 to 2025), Adaptive Biotechnologies's AFS securities has grown at a -51.8% compound annual growth rate (CAGR), from $118.53M to $13.23M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.